Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) just unveiled an announcement.
Telix Pharmaceuticals announced the approval of its first-generation PSMA-PET imaging product, Illuccix®, and its osteomyelitis imaging agent, Scintimun®, in multiple countries. These approvals enhance Telix’s market presence and demonstrate its commitment to advancing medical imaging technologies. The company also highlighted its miniaturized surgical gamma probe, SENSEI®, which is registered for use in the U.S. and Europe, further solidifying its position in the medical imaging sector.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals operates in the pharmaceutical industry, focusing on the development and commercialization of diagnostic and therapeutic products. Its primary products include the PSMA-PET imaging product Illuccix® and the osteomyelitis imaging agent Scintimun®. The company has obtained approvals for its products from various regulatory agencies worldwide, including the FDA, TGA, and MHRA, among others.
Average Trading Volume: 2,006,483
Technical Sentiment Signal: Buy
Current Market Cap: A$8.7B
Learn more about TLX stock on TipRanks’ Stock Analysis page.